Helen Louise Collins, CHIEF MEDICAL OFFICER at Enliven Therapeutics, Inc. (ELVN), sold 80,000 shares at $30.02 ($2.4M) on 2026-03-09, disclosed to the SEC on 2026-03-11.
Open-market sale of $2.4M ELVN by CHIEF MEDICAL OFFICER. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $30.02 | 29,871 | $897K | 37.3% |
| 2 | $30.02 | 29,871 | $897K | 37.3% |
| 3 | $30.19 | 10,129 | $306K | 12.7% |
| 4 | $30.19 | 10,129 | $306K | 12.7% |
| Total | $30.06 avg | 80,000 | $2.4M | 100% |
| Filing → |
| ELVN | SELL | 2026-07-21 | $263K | — | Filing → |
| ELVN | SELL | 2026-06-22 | $219K | — | Filing → |
| ELVN | SELL | 2026-05-20 | $199K | — | Filing → |